Grifols, S.A. (GRFS)

Oakmark International Small Cap Strategy Q2 2026 Portfolio Update

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency

Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript

Grifols Q2 Earnings Call Highlights

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst